Other Consolidated Financial Statement Detail (Tables)

9 Months Ended

Sep. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Other income (expense), net

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2013			2012			2013			2012
Interest income	$	1.5		$	5.9		$	6.7		$	22.6
Interest expense	(6.6		)	(8.7		)	(25.5		)	(23.1		)
Impairments of investments	—			(3.5		)	(1.7		)	(4.8		)
Gain (loss) on investments, net	3.9			1.3			14.0			15.6
Foreign exchange gains (losses), net	(3.1		)	0.1			(11.0		)	0.2
Other, net	(0.3		)	0.4			(12.0		)	3.1
Total other income (expense), net	$	(4.6	)	$	(4.5	)	$	(29.5	)	$	13.5

Accrued Expenses and Other

(In millions)	As of September 30, 2013		As of December 31, 2012
Employee compensation and benefits	261.5		248.5
Revenue-related rebates	247.4		191.0
Deferred revenue	240.7		148.0
Royalties and licensing fees	117.3		45.2
Clinical development expenses	57.1		51.6
Production expenses	43.6		45.6
Current portion of contingent consideration obligations	29.1		22.4
Construction in progress	21.9		12.3
Other	185.8		215.3
Total accrued expenses and other	$	1,204.4	$	979.9